Cardiac Sarcoidosis: FDG PET vs. Ga-DOTANOC PET
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01729169|
Recruitment Status : Completed
First Posted : November 20, 2012
Last Update Posted : May 11, 2016
|Condition or disease|
|Sarcoidosis Cardiac Sarcoidosis|
- Study A: Subjects with biopsy proven sarcoidosis suspected of cardiac involvement (prone to arrhythmias, cardiac failure, unexplained dyspnea) are studied twice: 1) 18-FDG PET preceded by 12 hours fasting and 2) 18-FDG PET performed during a 2 hour somatostatin blockade (300 microgram/hour)/Heparin infusion.
- Study B: Subjects with biopsy proven sarcoidosis suspected of cardiac involvement are studied twice: 1) 18-FDG PET preceded by 12 hours fasting and 2) 68Ga-DOTANOC PET preceded by at least 6 hours fasting.
|Study Type :||Observational|
|Actual Enrollment :||19 participants|
|Official Title:||Diagnosing Cardiac Sarcoidosis Using FDG PET: Optimization|
|Study Start Date :||June 2012|
|Actual Primary Completion Date :||January 2015|
|Actual Study Completion Date :||January 2015|
Patients with biopsy proven sarcoidosis suspected of having cardiac sarcoidosis
- Cardiac sarcoidosis - Sensitivity [ Time Frame: 01/01/2015 ]Ability to correctly identify patients with cardiac sarcoidosis
- Myocardial cardiac glucose uptake assessed by Cardiac SUV [ Time Frame: 01/01/2015 ]Semiquantitative assessment of myocardial glucose uptake, the Standardized Uptake Value (SUV). Expressed in g/ml.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01729169
|Aarhus University Hospital|
|Aarhus, Denmark, 8000|